Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy

In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lise Bertin, MD, Anthony Canellas, MD, Baptiste Abbar, MD, Marianne Veyri, Jean-Philippe Spano, MD, PhD, Jacques Cadranel, MD, PhD, Armelle Lavolé, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	HIV Anti–PD-1 CD4+ Viral load Lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ec6f4644ae4240f5bb7de65702a720dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec6f4644ae4240f5bb7de65702a720dc
record_format	dspace
spelling	oai:doaj.org-article:ec6f4644ae4240f5bb7de65702a720dc2021-12-02T05:03:48ZBrief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy2666-364310.1016/j.jtocrr.2021.100247https://doaj.org/article/ec6f4644ae4240f5bb7de65702a720dc2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321001065https://doaj.org/toc/2666-3643In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of patients with HIV suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here, we report the largest known study of patients with HIV with NSCLC (five patients) undergoing first-line immunotherapy by pembrolizumab, after CANCERVIH group selection. Our results are consistent with those of previous case reports concerning safety of immunotherapy in patients with HIV, revealing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome. Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also evaluated the effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients having rapid progression and two partial response. Nevertheless, besides safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV needs to be supported by larger studies.Lise Bertin, MDAnthony Canellas, MDBaptiste Abbar, MDMarianne VeyriJean-Philippe Spano, MD, PhDJacques Cadranel, MD, PhDArmelle Lavolé, MDElsevierarticleHIVAnti–PD-1CD4+Viral loadLung cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100247- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HIV Anti–PD-1 CD4+ Viral load Lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	HIV Anti–PD-1 CD4+ Viral load Lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
description	In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of patients with HIV suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here, we report the largest known study of patients with HIV with NSCLC (five patients) undergoing first-line immunotherapy by pembrolizumab, after CANCERVIH group selection. Our results are consistent with those of previous case reports concerning safety of immunotherapy in patients with HIV, revealing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome. Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also evaluated the effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients having rapid progression and two partial response. Nevertheless, besides safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV needs to be supported by larger studies.
format	article
author	Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD
author_facet	Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD
author_sort	Lise Bertin, MD
title	Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
title_short	Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
title_full	Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
title_fullStr	Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
title_full_unstemmed	Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
title_sort	brief report of anti–programmed cell death protein-1 in human immunodeficiency virus setting: relevant and breaking results in first-line nsclc therapy
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/ec6f4644ae4240f5bb7de65702a720dc
work_keys_str_mv	AT lisebertinmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT anthonycanellasmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT baptisteabbarmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT marianneveyri briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT jeanphilippespanomdphd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT jacquescadranelmdphd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT armellelavolemd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy
_version_	1718400686814658560

Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy

Ejemplares similares